Pharmaceuticals company AstraZeneca Pharma India announced Q2FY25 results Revenue from Operations: Rs 3,875.2 milllion compared to Rs 4,080.0 milllion during Q2FY24. PBT: Rs 424.0 milllion compared to Rs 510.3 milllion during Q2FY24. PAT: Rs -117.9 milllion compared to Rs 384.3 milllion during Q2FY24. Bhavana Agrawal, Chief Financial Officer AstraZeneca Pharma India, said: “We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31% bringing our H1 revenue from operations to Rs 7,955.2 milllion, driven by our portfolio -Oncology, Biopharmaceuticals and Rare Disease. The growth of the company is a derivative of our ambition to bring innovative medicines faster in the country for unmet patient needs”. Sanjeev Panchal, Country President & Managing Director, AstraZeneca Pharma India, said: “We are transforming the future of healthcare by unlocking the power of what science can do, for people, society, and planet. With a Growth Through Innovation strategy, we are constantly working towards expanding access to innovative therapies, progressive access strategies, and making healthcare systems resilient in India”. Result PDF